Patents by Inventor Deborah Parkes

Deborah Parkes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated human antibodies that bind epitopes on RG1
    Patent number: 7893217
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • Methods for treating disease-states associated with RG1 using immunoconjugates
    Patent number: 7887804
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 15, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • RG1 ANTIBODIES AND USES THEREOF
    Publication number: 20100081795
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: September 15, 2009
    Publication date: April 1, 2010
    Applicant: Bayer Schering Pharma
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20090292112
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: November 26, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • RG1 antibodies and uses thereof
    Patent number: 7611706
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 3, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • RG1 antibodies and uses thereof
    Patent number: 7608263
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 27, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20090214422
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 27, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • Purified pol DNA, a recombinant DNA construct for expression of HIV pol polypeptide sequences and a cell containing such construct
    Patent number: 7527925
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: May 5, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
  • Method for expressing HIV polypeptides
    Patent number: 7442525
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: October 28, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
  • RG1 antibodies and uses thereof
    Publication number: 20080226656
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: September 18, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • Recombinant DNA construct for HIV envelope polypeptides and polypeptides produced thereby
    Patent number: 7425428
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: September 16, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
  • Human immunodeficiency virus (HIV) nucleotide sequences
    Patent number: 7393949
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: July 1, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett
  • RG1 antibodies and uses thereof
    Publication number: 20080138899
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 12, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • RG1 antibodies and uses thereof
    Patent number: 7335748
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: February 26, 2008
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Patent number: 7307154
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: December 11, 2007
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • RG1 antibodies and uses thereof
    Publication number: 20050019845
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: July 20, 2004
    Publication date: January 27, 2005
    Applicant: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20040152139
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: July 22, 2003
    Publication date: August 5, 2004
    Applicant: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20040023307
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: July 8, 2003
    Publication date: February 5, 2004
    Applicant: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Douglas W. Schneider, Renate Parry
  • DNA encoding a novel RG1 polypeptide
    Patent number: 6682902
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: January 27, 2004
    Assignee: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Douglas W. Schneider, Renate Steinbrecher
  • HIV immunoassays using gag polypeptides
    Patent number: 6458527
    Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
    Type: Grant
    Filed: June 28, 1993
    Date of Patent: October 1, 2002
    Assignee: Chiron Corporation
    Inventors: Paul A. Luciw, Dino Dina, Kathelyn Steimer, Ray Sanchez Pescador, Carlos George-Nascimento, Deborah Parkes, Rob Hallewell, Philip J. Barr, Martha Truett